| Size | Price | Stock | Qty |
|---|---|---|---|
| 2mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg | |||
| Other Sizes |
Purity: ≥98%
| Targets |
Nitazoxanide D4 targets the same molecular targets as its non-deuterated parent compound. Nitazoxanide acts on pyruvate:ferredoxin oxidoreductase (PFOR) enzyme-dependent electron transfer reaction, a critical process for anaerobic energy metabolism in parasites. It also kills Mycobacterium tuberculosis and exhibits activity against a broad spectrum of viruses. As a labeled compound, Nitazoxanide D4 is used to study these mechanisms.
|
|---|---|
| ln Vitro |
Nitazoxanide reduces parasite growth in cell culture by more than 90% with little evidence of drug-associated cytotoxicity. Nitazoxanide is a new thiazolide antiparasitic agent that shows excellent in vitro activity against a wide variety of protozoa and helminths. Nitazoxanide and its metabolite tizoxanide are more active in vitro than metronidazole against G. intestinalis, E. histolytica and T. vaginalis. Nitazoxanide exhibits potent inhibition of both HBV and HCV replication. Nitazoxanide potentiates the effect of subsequent treatment with Nitazoxanide plus IFN, but not Nitazoxanide plus 2CmeC, in HCV replicon-containing cells. Nitazoxanide induces reductions in several HBV proteins (HBsAg, HBeAg, HBcAg) produced by 2.2.15 cells, but does not affect HBV RNA transcription. Nitazoxanide exhibits IC50, and IC90 values of 0.017 and 0.776 mg/mL respectively, against E. histolytica, 0.004 and 0.067 mg/mL against G. intestinalis, and 0.034 and 2.046 mg/mL against T. vaginalis. Nitazoxanide is more toxic than metronidazole and albendazole against E. histolytica.
In vitro, Nitazoxanide D4 exhibits the same biological activity as Nitazoxanide, which includes antiprotozoal, anthelmintic, and antiviral effects. It is used in antiviral research to study its efficacy against broad-spectrum viruses, offering insights into mechanisms and potential therapeutic pathways. Its deuterated form allows for precise quantification in biological samples. |
| ln Vivo |
Nitazoxanide is partially effective at reducing the parasite burden in a gnotobiotic piglet diarrhea model when given orally for 11 days at 250 mg/kg/day but not at 125 mg/kg/day. Nitazoxanide induces a drug-related diarrhea in piglets that might have influenced its therapeutic efficacy.
In vivo, Nitazoxanide D4 is used as a tracer to study the pharmacokinetics and metabolism of Nitazoxanide in animal models. It is not administered as a therapeutic agent itself but is used to track the distribution, metabolism, and elimination of the parent compound. Its use in research helps to understand the in vivo behavior of Nitazoxanide. |
| Enzyme Assay |
In vitro analytical assays for Nitazoxanide D4 primarily involve mass spectrometry (LC-MS/MS) or gas chromatography-mass spectrometry (GC-MS). It is used as an internal standard to correct for matrix effects and to ensure accurate quantification of Nitazoxanide in biological samples. A known amount of Nitazoxanide D4 is added to samples, and the ratio of the analyte to the internal standard is measured.
|
| Cell Assay |
In vitro cell-based assays for Nitazoxanide D4 are not typically performed, as it is a labeled compound used for analytical purposes. However, it can be used in cell culture studies to track the cellular uptake and metabolism of Nitazoxanide. Cells are treated with Nitazoxanide D4, and the intracellular concentrations of the labeled compound and its metabolites are measured by LC-MS/MS.
|
| Animal Protocol |
125, 250 mg/kg; oral | Gnotobiotic piglet diarrhea model
| ADME/Pharmacokinetics |
The pharmacokinetic properties of Nitazoxanide D4 reflect those of Nitazoxanide. Following oral administration, Nitazoxanide is rapidly hydrolyzed to its active metabolite, tizoxanide. It is highly protein-bound and eliminated primarily in feces and urine. Nitazoxanide D4 is used to study these processes, providing a precise understanding of the compound's absorption, distribution, metabolism, and excretion.
|
| Toxicity/Toxicokinetics |
Nitazoxanide D4 is a stable isotope-labeled compound and is considered to have low toxicity. As a research compound, it is intended for laboratory use only and is not for human therapeutic use. Standard safety precautions should be followed when handling this compound. It is typically supplied with a purity of ≥98%.
|
| References | |
| Additional Infomation |
Nitazoxanide D4 is a deuterium-labeled version of the antiparasitic and antiviral drug Nitazoxanide. It is used as an analytical standard for the quantification of Nitazoxanide in biological samples. It is also known as Nitazoxanide-d4, NTZ D4, and NSC-697855 D4. This product is for research use only and is not for human therapeutic use.
|
| Molecular Formula |
C12H9N3O5S
|
|---|---|
| Molecular Weight |
311.31
|
| Exact Mass |
311.051
|
| CAS # |
1246819-17-9
|
| Related CAS # |
Nitazoxanide;55981-09-4
|
| PubChem CID |
71751033
|
| Appearance |
White to off-white solid powder
|
| LogP |
2.825
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
21
|
| Complexity |
428
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[2H]C1=C(C(=C(C(=C1[2H])C(=O)NC2=NC=C(S2)[N+](=O)[O-])OC(=O)C)[2H])[2H]
|
| InChi Key |
YQNQNVDNTFHQSW-QFFDRWTDSA-N
|
| InChi Code |
InChI=1S/C12H9N3O5S/c1-7(16)20-9-5-3-2-4-8(9)11(17)14-12-13-6-10(21-12)15(18)19/h2-6H,1H3,(H,13,14,17)/i2D,3D,4D,5D
|
| Chemical Name |
[2,3,4,5-tetradeuterio-6-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl] acetate
|
| Synonyms |
NTZ D4; NSC 697855 D4; NSC-697855; NSC697855 D4; Nitazoxanide D4, Alinia, Colufase, Daxon, NitazoxamideD4
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2122 mL | 16.0612 mL | 32.1223 mL | |
| 5 mM | 0.6424 mL | 3.2122 mL | 6.4245 mL | |
| 10 mM | 0.3212 mL | 1.6061 mL | 3.2122 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Forward genetic screen for identification of NTZ resistant worm mutants.Mol Biochem Parasitol.2014 Jan;193(1):1-8. |
|---|
Dose response curves ofC. elegansmutants resistant to other classes of drugs to NTZ in a six day lethality assay.Mol Biochem Parasitol.2014 Jan;193(1):1-8. |
Combination of NTZ with albendazole (ALB) and pyrantel (PYR).Mol Biochem Parasitol.2014 Jan;193(1):1-8. |
Ivermectin (IVM) susceptibility of the two NTZ resistant mutants identified in forward genetic screens at 44–45 hours.Mol Biochem Parasitol.2014 Jan;193(1):1-8. |
|---|
Effect of NTZ onC. elegansN2 wild-type nematodes.Mol Biochem Parasitol.2014 Jan;193(1):1-8. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
